Education
About Us
Working with TipRanks
Follow Us
Lincoln Pharmaceuticals Ltd (IN:LINCOLN)
:LINCOLN
Top Page
Lincoln Pharmaceuticals Ltd
(LINCOLN)
Select Model
Select Model
Rating:74Outperform
Price Target:
₹556.00
▲(11.96% Upside)
The score is primarily supported by strong financial performance, led by a near-zero-debt balance sheet and solid profitability, with improved free cash flow in 2025. This is tempered by weaker technical trends (below key longer-term moving averages and negative MACD) and only moderate valuation support given the low dividend yield.
Lincoln Pharmaceuticals Ltd (LINCOLN) vs. iShares MSCI India ETF (INDA)
Market Cap
₹9.76B
Dividend Yield0.37%
Average Volume (3M)1.66K
Price to Earnings (P/E)12.2
Beta (1Y)1.66
Revenue GrowthN/A
EPS GrowthN/A
CountryIN
Employees1,687
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)9.98
Shares Outstanding20,029,728
10 Day Avg. Volume3,133
30 Day Avg. Volume1,664
Financial Highlights & Ratios
PEG Ratio-1.14
Price to Book (P/B)1.65
Price to Sales (P/S)1.77
P/FCF Ratio14.99
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)5,441.57
Revenue Forecast (FY)₹667.26B
Lincoln Pharmaceuticals Ltd Business Overview & Revenue Model
Company DescriptionLincoln Pharmaceuticals Limited engages in manufacturing and trading of pharmaceutical products in India and internationally. The company's product portfolio includes dermatologist preparations, gynecological products, gastrointestinal ranges, otology products, and phosphodiesterase type 5 inhibitor and general anesthetics. It provides products in the areas of cough and cold, anti-allergic, and anti-asthmatics; sterile ophthalmic eye drops and ointment; anti-malarial; vitamins, minerals, and antioxidants; anti-bacterial, anti-viral, and anti-fungal vitamins; analgesic and anti-pyretic; anti-psychotic, anti-convulsant, anti-depressant, and anti-diabetic; cardiac anti-hypertensives, and diuretic; and anti-diarrheal, anti-spasmodic, and laxative. The company also offers branded generics. Lincoln Pharmaceuticals Limited was founded in 1979 and is based in Ahmedabad, India.
How the Company Makes Money
Lincoln Pharmaceuticals Ltd Financial Statement Overview
Summary
Income Statement
Balance Sheet
Cash Flow
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 6.30B | 6.23B | 5.81B | 5.05B | 4.68B | 4.15B |
| Gross Profit | 3.40B | 3.32B | 2.97B | 2.59B | 2.46B | 2.13B |
| EBITDA | 1.30B | 1.24B | 1.34B | 1.12B | 1.05B | 928.43M |
| Net Income | 863.50M | 823.46M | 933.05M | 728.99M | 693.55M | 622.50M |
Balance Sheet | ||||||
| Total Assets | 0.00 | 7.97B | 7.00B | 5.87B | 5.34B | 4.52B |
| Cash, Cash Equivalents and Short-Term Investments | 1.96B | 1.96B | 1.52B | 1.14B | 1.15B | 945.06M |
| Total Debt | 0.00 | 0.00 | 10.67M | 19.97M | 20.44M | 5.20M |
| Total Liabilities | -6.72B | 1.25B | 1.07B | 849.46M | 1.01B | 859.67M |
| Stockholders Equity | 6.72B | 6.72B | 5.93B | 5.02B | 4.33B | 3.66B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | 737.71M | 237.41M | 249.80M | 306.07M | 605.19M |
| Operating Cash Flow | 0.00 | 930.15M | 632.17M | 392.62M | 761.32M | 692.70M |
| Investing Cash Flow | 0.00 | -789.47M | -573.42M | -366.43M | -780.80M | -642.27M |
| Financing Cash Flow | 0.00 | -64.02M | -51.80M | -45.01M | -25.56M | -57.45M |
Lincoln Pharmaceuticals Ltd Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | ₹9.76B | 12.20 | ― | 0.37% | ― | ― | |
64 Neutral | ₹7.63B | 14.33 | ― | ― | 8.92% | -5.56% | |
62 Neutral | ₹7.72B | 19.93 | ― | 1.92% | 14.09% | -34.41% | |
57 Neutral | ₹5.85B | 19.95 | ― | ― | 32.95% | 67.39% | |
57 Neutral | ₹7.21B | 40.94 | ― | 1.96% | -6.96% | -66.75% | |
54 Neutral | ₹9.07B | -33.60 | ― | 0.48% | -18.86% | -150.92% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
IN:LINCOLN
Lincoln Pharmaceuticals Ltd
487.35
-278.18
-36.34%
IN:KILITCH
Kilitch Drugs (India) Limited
334.55
26.29
8.53%
IN:KOPRAN
Kopran Limited
149.35
-37.21
-19.95%
IN:THEMISMED
Themis Medicare Limited
98.50
-147.30
-59.93%
IN:WANBURY
Wanbury Limited
218.85
-9.10
-3.99%
IN:ANUHPHR
Anuh Pharma Limited
77.00
-22.67
-22.75%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.